Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
Dateline City:
KENILWORTH, N.J. Results of First Phase 3 Trial Anticipated in Late 2017KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the publication of research conducted by Merck
scientists on the discovery and development of verubecestat, an
investigational small molecule inhibitor of the enzyme beta-site amyloid
precursor protein cleaving enzyme 1 (BACE1), for the potential treatment
of Alzheimer ’s disease (AD).Language:
EnglishContact: MerckMedia:Pam Eisele, 267-305-3558orIan McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK alzheimers NYSE:MRK verubecestat Source Type: news